Metronidazole

DRUG INFORMATION

  ADULT
    - Trichomoniasis: Adult Female and Male Patients: One-day treatment: 2 g (20 mL) of
      LIKMEZ, given either as a single oral dose or in 2 divided oral doses of 1 g (10
      mL) each, given on the same day.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Seven-day course of treatment: 250 mg (2.5 mL) of LIKMEZ given three times
      daily for 7 consecutive days.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Amebiasis: Adult Patients: For acute intestinal amebiasis (acute amebic
      dysentery): 750 mg (7.5 mL) orally three times daily for 5 days to 10 days.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of LIKMEZ for the treatment of amebiasis have been
      established in pediatric patients. The safety and effectiveness of LIKMEZ for the
      treatment of trichomoniasis and anaerobic bacterial infections have not been
      established in pediatric patients.
      Source: US FDA label for metronidazole (LIKMEZ), section 'pediatric use',
      retrieved 2026-08-29
    - Trichomoniasis: Adult Female and Male Patients: One-day treatment: 2 g (20 mL) of
      LIKMEZ, given either as a single oral dose or in 2 divided oral doses of 1 g (10
      mL) each, given on the same day. ( 2.1 ) Seven-day course of treatment: 250 mg
      (2.5 mL) of LIKMEZ given three times daily for 7 consecutive days. ( 2.1 )
      Individualize the dosing regimen.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) Pediatric Patients : 35 mg/kg/24 hours to 50 mg/kg/24 hours, divided into
      three doses, to a maximum dose of 2,250 mg/24 hours (maximum dose 750 mg/dose or
      7.5 mL/dose),orally for 10 days.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - The clearance of metronidazole will depend on the type of dialysis membrane used,
      the duration of the dialysis session, and other factors.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - No adjustment in LIKMEZ dose is needed in patients undergoing continuous
      ambulatory peritoneal dialysis (CAPD) [ see Clinical Pharmacology (12.3) ] . 2.6
      Important Administration Instructions Shake the bottle well before administering
      the recommended dosage.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - Decreased liver function in geriatric patients can result in increased
      concentrations of metronidazole that may necessitate adjustment of metronidazole
      dosage [ see Dosage and Administration (2.4) ]. 8.6 Renal Impairment Patients with
      end-stage renal disease may excrete metronidazole and metabolites slowly in the
      urine, resulting in significant accumulation of metronidazole metabolites.
      Source: US FDA label for metronidazole (LIKMEZ), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - ( 2.3 ) Patients with Severe Hepatic Impairment (Child-Pugh C) Reduce the dose of
      LIKMEZ by 50%.
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - Do not exceed a maximum of 4 g (40 mL) during a 24-hour period. 2.4 Recommended
      Dosage in Patients with Severe Hepatic Impairment For patients with severe hepatic
      impairment (Child-Pugh C), reduce the dose of LIKMEZ by 50% [ see Use in Specific
      Populations (8.7) and Clinical Pharmacology (12.3) ].
      Source: US FDA label for metronidazole (LIKMEZ), section 'dosage and
      administration', retrieved 2026-08-29
    - Monitor for LIKMEZ associated adverse reactions [ see Clinical Pharmacology (12.3)
      ] . 8.7 Hepatic Impairment Patients with hepatic impairment metabolize
      metronidazole slowly, with resultant accumulation of metronidazole in the plasma.
      Source: US FDA label for metronidazole (LIKMEZ), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary While available studies cannot definitively establish the absence of
      risk, published data from case-control studies, cohort studies and meta-analyses
      have not established an association with metronidazole use during pregnancy and
      major birth defects, miscarriage or other adverse maternal or fetal outcomes (see
      Data).
      Source: US FDA label for metronidazole (LIKMEZ), section 'pregnancy', retrieved
      2026-08-29
    - The background risk of major birth defects and miscarriage for the indicated
      population is unknown.
      Source: US FDA label for metronidazole (LIKMEZ), section 'pregnancy', retrieved
      2026-08-29
    - All pregnancies have a background risk of birth defect, loss, or other adverse
      outcomes.
      Source: US FDA label for metronidazole (LIKMEZ), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Lactation : A lactating woman may choose to pump and discard human milk for the
      duration of LIKMEZ therapy and for 48 hours after the last dose and feed her
      infant stored human milk or formula.
      Source: US FDA label for metronidazole (LIKMEZ), section 'use in specific
      populations', retrieved 2026-08-29
    - There was no evidence of harm to the fetus due to metronidazole. 8.2 Lactation
      Risk Summary Metronidazole is present in human milk at concentrations similar to
      maternal serum levels, and infant serum levels can be close to or comparable to
      infant therapeutic levels.
      Source: US FDA label for metronidazole (LIKMEZ), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for LIKMEZ and any potential adverse effects on
      the breastfed infant from LIKMEZ or from the underlying maternal condition.
      Source: US FDA label for metronidazole (LIKMEZ), section 'use in specific
      populations', retrieved 2026-08-29